Company intelligence / Profile preview

EyeSense

Basel, Basel City, Switzerlandeyesense.com ↗

Ownership: Private
Employees: ~10
Development stage: Preclinical

Overview

EyeSense has developed a novel continuous glucose monitoring system based on fiber optic biosensor technology embedded in a hydrogel. Clinical studies have shown promising accuracy and reliability. The device offers extended wear time (up to four weeks), is minimally invasive/painless, and aims to reduce costs while improving quality of life for diabetes patients. Marketing authorization application is pending as of 2024

Therapeutic areas: Endocrinology
Modalities: DeviceHydrogel-based drug delivery therapy
Industry: Physiological Monitoring

Partnerships

Lee’s Pharmaceutical Holdings Limited (Lee’s PHARM)

Beyond the preview

Go deeper on EyeSense.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EyeSense.

Explore the full profile